BioMarin Pharmaceutical Inc. (BMRN): Price-to-Sales Ratio

Corporate company logo of BioMarin Pharma (BMRN)

BioMarin Pharmaceutical (BMRN) dominates the therapy of rare genetic pathologies, possessing exceptional pricing power. The price-to-sales valuation reflects the dynamics of this superiority, where the value 3.00 captures this metric. Process optimization through the outsourcing of clinical trials accelerates the release of innovations. High patent barriers and FDA protection make the company's scientific foundation virtually inaccessible to competitors.

BMRN: BioMarin Pharmaceutical P/S Multiple 07/04/2022 - 11/13/2026

Metric breakdowns and analytics for BioMarin Pharma (BMRN)

- share price and consensus valuation forecast:
Price Performance Chart biomarin.com|BMRN - Price Target Chart
- stock exchange capitalization data:
Market Valuation BioMarin Pharma|BMRN - Enterprise Value
- balance sheet net asset value indicators:
Accounting Value of a Share BioMarin|BMRN - Book Capitalization|Market Capitalization to Book Value Ratio biomarin.com|BMRN - Aggregate Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio BioMarin Pharmaceutical|BMRN - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio BioMarin Corp|BMRN - Company Aggregate Debts|Debts to Book Capitalization BioMarin Pharma|BMRN - Company Long-Term Debts|Company Short-Term Debt BioMarin|Interim Coverage Ratio biomarin.com
- earnings and valuation multiples information:
BMRN - Company Net Income|Expected Net Profit BioMarin Pharmaceutical|BMRN - Price to Earnings Ratio|Projected Price to Earnings BioMarin Pharmaceutical Inc.|BMRN - PEG Multiple|EV/EBITDA Multiple BioMarin Pharma|BMRN - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year BioMarin|BMRN - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months biomarin.com|BMRN - Earnings per share growth in current year|Projected earnings per share growth rate for next year BioMarin Pharmaceutical
- issuer revenue and sales details:
BMRN - Company Sales|Company Future Revenue biomarin.com|BMRN - Price-to-Revenue Ratio|Future Price to Revenue BioMarin Pharma
General company analysis:BMRN biomarin.com
Finished products of BioMarin Pharmaceutical

For gene therapy innovator BioMarin Pharmaceutical (BMRN), this indicator serves as a tool for assessing market value relative to the generated revenue stream. By analyzing the price-to-sales ratio per share, an investor determines the premium for R&D scientific and technological potential, where market capitalization is divided by annual sales volume to identify whether the asset is overvalued or the business is fundamentally undervalued.

Competing companies

VRTX (vrtx.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alnylam ALNY|INSM (Insmed Inc.) - Price-to-Sales Ratio|United Therapeutics Corp. - P/S Multiple|Market Capitalization-to-Revenue Ratio BBIO (BridgeBio Corp)|BGM: P/S Multiple|cogentbio.com (COGT) - P/S Multiple|Price-to-Revenue Ratio Xeris Biopharma Holdings|KROS: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Arcturus Pharma (ARCT)|Market Cap to Revenue Eton Corp ETON|P/S Multiple KMDA (Kamada Ltd.)|P/S Multiple fulcrumtx.com FULC|Abeona - P/S Multiple|MREO: Price-to-Revenue Ratio|PLX: P/S Multiple|PLRX - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Applied Therapeutics|Price to Sales aileronrx.com RNTX|Price-to-Revenue Ratio Gelteq Limited (GELS)|Market Cap to Revenue aytubio.com AYTU|P/S Multiple CMMB (Chemomab Therapeutics Ltd.)|P/S Multiple SRx Health Solutions Inc SRXH|PLRZ - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio AEZS (Aeterna Zentaris)|CYTH: P/S Multiple|INZY - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Reneo Pharma|Market Cap to Revenue Ratio CSCI (COSCIENS Bio)